Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 11771
Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645744(US20240018151, Example 17 | US20240018151, Example...)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645763(US20240018151, Example 28)
Affinity DataKd:  3nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645762(US20240018151, Example 25)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645761(US20240018151, Example 24)
Affinity DataKd:  3nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645760(US20240018151, Example 20)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645759(US20240018151, Example 19)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645758(US20240018151, Example 18)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645744(US20240018151, Example 17 | US20240018151, Example...)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645749(US20240018151, Example 15 | US20240018151, Example...)
Affinity DataKd:  3nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645755(US20240018151, Example 14)
Affinity DataKd: <1nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645754(US20240018151, Example 11)
Affinity DataKd: <1nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645749(US20240018151, Example 15 | US20240018151, Example...)
Affinity DataKd:  7.5nMAssay Description:Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645752(US20240018151, Example 9)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645751(US20240018151, Example 8)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645749(US20240018151, Example 15 | US20240018151, Example...)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645747(US20240018151, Example 4)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645746(US20240018151, Example 3)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645745(US20240018151, Example 2)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645744(US20240018151, Example 17 | US20240018151, Example...)
Affinity DataIC50: 50nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645750(US20240018151, Example 7)
Affinity DataIC50: 525nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645753(US20240018151, Example 10)
Affinity DataIC50: 1.00E+3nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Target1-phosphatidylinositol 3-phosphate 5-kinase(Human)
Tme Therapeutics

US Patent
LigandPNGBDBM645748(US20240018151, Example 5)
Affinity DataIC50: 1.00E+3nMAssay Description:Briefly, 4 compound solution and 4 ATP solution are prepared with assay buffer (50 mM MOPS, 1 mM DTT, pH7.2). 4 Substrate solution and 4 kinase/Metal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent